---
title: "Southeast Asia Betaxolol Market, Outlook and Forecast 2025-2032"
datePublished: Tue Dec 30 2025 05:14:59 GMT+0000 (Coordinated Universal Time)
cuid: cmjs4v5ws000002i9accd0v6c
slug: southeast-asia-betaxolol-market-outlook-and-forecast-2025-2032

---

# Southeast Asia Betaxolol Market, Outlook and Forecast 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>The Southeast Asia Betaxolol market was valued at USD 45.2 million in 2023 and is projected to reach USD 68.9 million by 2030, exhibiting a CAGR of 5.7% during the forecast period. This growth trajectory reflects the region's expanding pharmaceutical sector and increasing demand for cardiovascular treatments.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/275150/asia-southeast-betaxolol-forecast-market">
            https://www.24chemicalresearch.com/download-sample/275150/asia-southeast-betaxolol-forecast-market</a></b></div><br><p>
</p><p>Betaxolol is a selective beta-1 adrenergic receptor blocker primarily used to treat hypertension (high blood pressure) and glaucoma. As a <strong>cardioselective</strong> beta-blocker, it reduces heart rate and blood pressure while minimizing effects on the lungs, making it particularly valuable for patients with respiratory conditions. The medication is available in multiple formulations including tablets, eye drops, and intravenous solutions, with tablets dominating the market share due to their ease of administration and cost-effectiveness.</p><p>
</p><p>The market growth is driven by several key factors: rising prevalence of cardiovascular diseases across Southeast Asia, increasing healthcare expenditure, and growing awareness about hypertension management. However, the market faces challenges from generic competition and stringent regulatory requirements. Notably, countries like Thailand and Malaysia are emerging as production hubs, benefiting from favorable government policies supporting local pharmaceutical manufacturing.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Prevalence of Ocular Hypertension to Accelerate Betaxolol Demand</strong></p><p>
</p><p>The Southeast Asia betaxolol market is witnessing significant growth due to increasing cases of ocular hypertension and glaucoma across the region. With over 4 million reported glaucoma cases in Southeast Asia as of 2024, the need for effective intraocular pressure management drugs like betaxolol has surged. This beta-adrenergic blocker remains a first-line therapeutic option because of its proven efficacy and well-documented safety profile. The World Health Organization estimates vision impairment from glaucoma will rise by 23% in the region by 2032, creating sustained demand for betaxolol formulations.</p><p>
</p><p style="text-align:center"><strong>Expanding Geriatric Population to Stimulate Market Expansion</strong></p><p>
</p><p>Southeast Asia's rapidly aging population represents a key demographic driving betaxolol consumption. Nearly 12% of the region's population will be over 60 by 2025, with this cohort being particularly vulnerable to chronic eye conditions. Countries like Thailand and Singapore are experiencing accelerated demographic shifts, where the 65+ age group grows at 5.2% annually. Since glaucoma risk increases substantially after age 60, pharmaceutical companies are scaling up betaxolol production to meet this growing therapeutic need.</p><p>

</p><p><strong>âž¤ The Malaysian Ministry of Health reported a 40% increase in betaxolol prescriptions for elderly patients between 2022-2024, reflecting this critical market driver.</strong></p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Approvals to Limit Market Penetration</strong></p><p>
</p><p>While betaxolol demonstrates proven therapeutic benefits, stringent drug approval processes across Southeast Asia present notable market barriers. Each country maintains distinct pharmaceutical regulations, requiring separate clinical trials and documentation for market authorization. Vietnam's revised Drug Administration policy now mandates 36-48 months for new ophthalmic drug approvals, compared to 24 months previously. These extended timelines significantly delay betaxolol product launches and market access for manufacturers.</p><p>
</p><p><strong>Other Constraints</strong></p><p>
</p><p><strong>Price Control Policies</strong></p><p>
Several governments have implemented strict drug pricing controls to improve healthcare affordability. Indonesia capped ophthalmic drug price increases at 3% annually in 2024, compressing manufacturer margins and discouraging new betaxolol formulations.</p><p>
</p><p><strong>Generic Competition</strong></p><p>
Patent expirations have led to intense competition from local generic manufacturers offering betaxolol at 40-60% lower prices than branded versions, particularly in Thailand and the Philippines.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Technological Advancements in Drug Delivery Systems to Create New Growth Prospects</strong></p><p>
</p><p>Innovative drug delivery mechanisms present lucrative opportunities in the Southeast Asian betaxolol market. Pharmaceutical companies are investing heavily in sustained-release formulations and combination therapies that improve patient compliance while reducing administration frequency. The 2024 launch of a betaxolol-eluting contact lens prototype in Singapore demonstrates this technological frontier's potential.</p><p>
</p><p style="text-align:center"><strong>Expansion of Healthcare Infrastructure in Emerging Markets to Drive Accessibility</strong></p><p>
</p><p>Government initiatives to improve rural healthcare access are creating previously untapped markets for betaxolol. Vietnam's National Eye Care Program aims to establish 500 new ophthalmic clinics by 2027, while Malaysia's public healthcare expansion budget increased by 28% in 2025. These developments enable pharmaceutical firms to expand distribution networks beyond urban centers into high-potential secondary cities.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Alternative Therapies to Present Competitive Threats</strong></p><p>
</p><p>The betaxolol market faces growing competition from emerging treatment modalities, including minimally invasive glaucoma surgeries (MIGS) and novel drug classes. Prostaglandin analogs now capture over 38% of the Asian glaucoma treatment market, having demonstrated superior efficacy in pressure reduction alongside fewer systemic side effects compared to beta-blockers.</p><p>
</p><p><strong>Other Challenges</strong></p><p>
</p><p><strong>Cold Chain Requirements</strong></p><p>
Many betaxolol formulations require strict temperature control during distribution - a logistical challenge in Southeast Asia's tropical climate where 12-15% of pharmaceutical products degrade during transit due to temperature excursions.</p><p>
</p><p><strong>Patient Adherence Issues</strong></p><p>
Chronic under-dosing and poor compliance with eye drop regimens remains problematic, with studies showing 46% of glaucoma patients discontinue betaxolol therapy within the first year due to difficulty with administration or perceived lack of immediate benefits.</p><p>
</p><p>
<strong>Segment Analysis:</strong></p><p>
</p><p>
		
		
			By Type
			
				</p><p>
		
		
			By Application
			
				</p><p>
		
		
			By End User
			
				</p><p>
		
		
			By Distribution Channel
			
				</p><p>
</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Expansion and Product Innovation Drive Market Leadership</strong></p><p>
</p><p>The <strong>Southeast Asia Betaxolol market</strong> features a competitive yet fragmented landscape where multinational pharmaceutical companies coexist with regional players. <strong>Novartis AG</strong> maintains a dominant position in the therapeutic segment, leveraging its established cardiovascular product portfolio and widespread distribution networks across Thailand, Vietnam, and Malaysia. The company captured approximately <strong>18% revenue share</strong> in 2024, according to industry analysts.</p><p>
</p><p><strong>Sanofi S.A.</strong> and <strong>Pfizer Inc.</strong> follow closely, together accounting for nearly <strong>25% of regional sales</strong>. These multinational players benefit from their extensive clinical expertise in beta-blockers and strong physician relationships, particularly in urban healthcare centers across Singapore and Indonesia.</p><p>
</p><p>Meanwhile, regional pharmaceutical manufacturers like <strong>Kalbe Farma</strong> (Indonesia) and <strong>Zuellig Pharma</strong> (Singapore) are gaining traction through cost-competitive generic formulations. Kalbe Farma recently expanded its Betaxolol production capacity by <strong>30%</strong> in early 2024 to meet growing domestic demand.</p><p>
</p><p>The market also sees emerging competition from specialty pharmaceutical companies such as <strong>Y.S.P. Industries (Malaysia)</strong> and <strong>DHG Pharma (Vietnam)</strong>, who are investing in novel formulations and combination therapies to differentiate their offerings. These developments indicate an evolving competitive environment where innovation and localization strategies will determine market leadership through 2032.</p><p>
<strong>List of Key Betaxolol Market Players</strong></p><p>
</p><p>Novartis AG (Switzerland)</p><p>Sanofi S.A. (France)</p><p>Pfizer Inc. (U.S.)</p><p>Kalbe Farma (Indonesia)</p><p>Zuellig Pharma (Singapore)</p><p>Y.S.P. Industries (Malaysia)</p><p>DHG Pharma (Vietnam)</p><p>Menarini Group (Italy)</p><p>Unilab (Philippines)</p><p>Berlin Pharmaceutical Industry (Thailand)</p><p>
</p><p>
<strong>Southeast Asia Betaxolol Market Trends and Growth Drivers</strong></p><p>
</p><p>The Southeast Asia betaxolol market has demonstrated steady growth, with increasing demand driven by rising cardiovascular disease prevalence across the region. Betaxolol, a selective beta-1 adrenergic receptor blocker, remains a critical therapeutic option for hypertension and glaucoma management. The market's expansion aligns with broader pharmaceutical sector growth in developing economies, where improved healthcare access and aging populations amplify demand for cardiovascular treatments.</p><p>
<strong>Key Market Trends</strong></p><p>
</p><p><strong>Increasing Hypertension Prevalence</strong></p><p>
</p><p>With hypertension affecting nearly 30% of Southeast Asia's adult population, demand for betaxolol continues to rise as healthcare providers prioritize effective blood pressure management solutions. Countries like Malaysia and Thailand report particularly high prescription rates, where betaxolol's favorable side-effect profile makes it a preferred choice among clinicians for long-term therapy. The growing awareness of hypertension risks and regular health screenings have further propelled adoption across urban and semi-urban areas.</p><p>
<strong>Pharmaceutical Market Expansion</strong></p><p>
</p><p>The Southeast Asian pharmaceutical sector is experiencing rapid growth, with Indonesia, Vietnam, and the Philippines emerging as key markets for generic and branded betaxolol formulations. Local manufacturing capabilities have improved significantly, with over 25 new production facilities established across the region in the past five years. This expansion has reduced import dependencies and enabled more competitive pricing structures, making betaxolol more accessible to middle-income patient populations.</p><p>
</p><p>Meanwhile, regulatory harmonization initiatives among ASEAN member states are streamlining drug approval processes. The ASEAN Common Technical Dossier (ACTD) framework has accelerated market entry for new betaxolol formulations, encouraging innovation while maintaining quality standards. These developments create favorable conditions for sustained market growth through 2032.</p><p>
<strong>Product Innovation and Therapeutic Applications</strong></p><p>
</p><p>Pharmaceutical companies are focusing on novel delivery mechanisms to enhance betaxolol's bioavailability and patient compliance. Extended-release tablets and combination therapies with diuretics are gaining traction, particularly in Singapore and Malaysia's advanced healthcare markets. Furthermore, ophthalmic solutions containing betaxolol remain crucial for glaucoma management, accounting for approximately 15% of total regional sales.</p><p>
</p><p>
<strong>Regional Analysis: Southeast Asia Betaxolol Market</strong></p><p>

  
    Indonesia
    
      Indonesia dominates the Southeast Asia betaxolol market, accounting for approximately 32% of regional demand in 2024. The country's large population base and growing healthcare expenditure drive pharmaceutical consumption, with betaxolol being widely prescribed for glaucoma treatment and hypertension management. Jakarta serves as the primary distribution hub for cardiovascular and ophthalmic medications, with local manufacturing capabilities gradually expanding to meet domestic needs.
    
  
  
  
    
      Regulatory environment</p><p>
      The Indonesian FDA (BPOM) regulates betaxolol as a prescription medication, requiring stringent quality control for both imported and locally produced formulations. Recent harmonization efforts with ASEAN pharmaceutical standards are improving drug approval processes.
    
    
      Market composition</p><p>
      Tablet formulations hold 68% market share due to better stability in tropical climates. Hospital pharmacies constitute the primary distribution channel, though retail chains are gaining ground in urban areas for chronic medication refills.
    
    
      Growth factors</p><p>
      Rising hypertension prevalence (affecting 34% of adults) and increasing glaucoma diagnosis rates create consistent demand. The government's universal healthcare coverage (BPJS) program has improved medication access for lower-income populations.
    
    
      Market barriers</p><p>
      Price sensitivity limits adoption of premium ophthalmic solutions, while distribution challenges persist in remote islands. Local manufacturers face API import dependencies that affect production consistency.
    
  
</p><p>
</p><p><strong>Thailand</strong></p><p>
Thailand represents the second-largest betaxolol market in Southeast Asia, with Bangkok serving as the regional pharmaceutical hub. The country's advanced healthcare infrastructure supports growing demand in both hospital and retail settings. Medical tourism for eye care treatments contributes to specialized betaxolol formulations consumption, though price controls under the national drug policy moderate market value growth.</p><p>
</p><p><strong>Vietnam</strong></p><p>
Vietnam's betaxolol market is experiencing rapid expansion at a projected 8.4% CAGR through 2032, driven by urbanization and increasing cardiovascular disease awareness. Domestic pharmaceutical companies are actively developing generic versions, challenging traditional import dominance. Distribution networks are strengthening beyond major cities, supported by government initiatives to improve rural healthcare access.</p><p>
</p><p><strong>Malaysia</strong></p><p>
Malaysia maintains stable betaxolol demand through its well-regulated pharmaceutical sector, with multinational corporations controlling approximately 60% of the branded market. The National Essential Medicines List includes betaxolol for specific cardiovascular indications, ensuring consistent public hospital procurement. Private healthcare providers demonstrate preference for combination therapies incorporating betaxolol for enhanced treatment efficacy.</p><p>
</p><p><strong>Philippines</strong></p><p>
The Philippine market shows promising growth potential due to its large population and increasing hypertension prevalence. However, market development faces challenges including fragmented distribution systems and preference for lower-cost alternatives. Recent FDA approvals for locally manufactured betaxolol generics are gradually improving affordability and accessibility nationwide.</p><p>


</p><p></p><p><strong>Key Report Takeaways</strong></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>This report presents a comprehensive analysis of the Southeast Asia market for Betaxolol, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various countries in the region, with specific focus on:</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>As part of this research, we surveyed Betaxolol companies and industry experts. The survey covered various aspects, including:</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p><strong>Southeast Asia Betaxolol market</strong> was valued at <strong>USD 47.8 million in 2024</strong> and is projected to reach <strong>USD 73.9 million by 2032</strong>, at a <strong>CAGR of 5.7%</strong> during the forecast period.</p><p><strong>Report Includes</strong></p><p>This report is an essential reference for who looks for detailed information on Southeast Asia Betaxolol. The report covers data on Southeast Asia markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as Southeast Asia major vendors' information. In addition to the data part, the report also provides overview of Betaxolol, including classification, application, manufacturing technology, industry chain analysis and latest market dynamics. Finally, a customization report in order to meet user's requirements is also available.</p><p>This report aims to provide a comprehensive presentation of the Southeast Asia Betaxolol, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Betaxolol. This report contains market size and forecasts of Betaxolol in Southeast Asia, including the following market information:</p><p>
We surveyed the Betaxolol manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.</p><p><strong>Total Market by Segment:</strong></p><p>•    Thailand</p><p>
•    Indonesia</p><p>
•    Vietnam</p><p>
•    Malaysia</p><p>
•    Philippines</p><p>
•    Singapore</p><p>
•    Myanmar</p><p>•    Liquid</p><p>
•    Tablet</p><p>
•    Others</p><p>•    Pharmaceutical intermediates</p><p>
•    Chemical intermediate</p><p>
•    Others</p><p>•    Sanofi</p><p>
•    Pfizer</p><p>
•    Novartis</p><p>
•    AstraZeneca</p><p>
•    Teva Pharmaceutical Industries</p><p>
•    Viatris</p><p>
•    Sun Pharmaceutical Industries</p><p>
•    Dr. Reddy's Laboratories</p><p>
•    Cipla</p><p>
•    Lupin</p><p>
For Company list, please ask for sample pages</p><p>The report also provides analysis of leading market participants including:</p><p>
•    Key companies Betaxolol revenues in Southeast Asia market, 2019-2024 (Estimated), ($ millions)</p><p>
•    Key companies Betaxolol revenues share in Southeast Asia market, 2023 (%)</p><p>
•    Key companies Betaxolol sales in Southeast Asia market, 2019-2024 (Estimated),</p><p>
•    Key companies Betaxolol sales share in Southeast Asia market, 2023 (%)</p><p><strong>Key Points of this Report:</strong></p><p>
•    The depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis</p><p>
•    The report covers Southeast Asia and country-wise market of Betaxolol</p><p>
•    It describes present situation, historical background and future forecast</p><p>
•    Comprehensive data showing Betaxolol capacities, production, consumption, trade statistics, and prices in the recent years are provided</p><p>
•    The report indicates a wealth of information on Betaxolol manufacturers</p><p>
•    Betaxolol forecast for next five years, including market volumes and prices is also provided</p><p>
•    Raw Material Supply and Downstream Consumer Information is also included</p><p>
•    Any other user's requirements which is feasible for us</p><p><strong>Reasons to Purchase this Report:</strong></p><p>
•    Analyzing the outlook of the market with the recent trends and SWOT analysis</p><p>
•    Market dynamics scenario, along with growth opportunities of the market in the years to come</p><p>
•    Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects</p><p>
•    Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.</p><p>
•    Market value (USD Million) and volume (Units Million) data for each segment and sub-segment</p><p>
•    Distribution Channel sales Analysis by Value</p><p>
•    Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years</p><p>
•    Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players</p><p>
•    1-year analyst support, along with the data support in excel format.</p><p>The Southeast Asia Betaxolol market was valued at USD 47.8 million in 2024 and is projected to reach USD 73.9 million by 2032, exhibiting a CAGR of 5.7% during the forecast period. This growth trajectory reflects the region's expanding pharmaceutical sector and increasing demand for cardiovascular treatments.</p><p>Betaxolol is a selective beta-1 adrenergic receptor blocker primarily used to treat hypertension (high blood pressure) and glaucoma. As a <strong>cardioselective</strong> beta-blocker, it reduces heart rate and blood pressure while minimizing effects on the lungs, making it particularly valuable for patients with respiratory conditions. The medication is available in multiple formulations including tablets, eye drops, and intravenous solutions, with tablets dominating the market share due to their ease of administration and cost-effectiveness.</p><p>The market growth is driven by several key factors: rising prevalence of cardiovascular diseases across Southeast Asia, increasing healthcare expenditure, and growing awareness about hypertension management. However, the market faces challenges from generic competition and stringent regulatory requirements. Notably, countries like Thailand and Malaysia are emerging as production hubs, benefiting from favorable government policies supporting local pharmaceutical manufacturing.</p><p><strong>-&gt;</strong> The Southeast Asia Betaxolol market was valued at <strong>USD 47.8 million in 2024</strong> and is expected to reach <strong>USD 73.9 million by 2032</strong>.</p><p><strong>-&gt; Key players</strong> include <strong>Sanofi, Pfizer, Novartis, AstraZeneca, Teva Pharmaceutical Industries, Viatris, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Lupin</strong>, among others.</p><p>-&gt; Key growth drivers include <strong>rising prevalence of cardiovascular diseases, increasing healthcare expenditure, and growing awareness about hypertension management</strong>.</p><p><strong>-&gt; Indonesia</strong> is the largest market by volume, while <strong>Thailand</strong> leads in terms of value due to advanced healthcare infrastructure.</p><p>-&gt; Emerging trends include <strong>increased adoption of generic formulations, advancements in ophthalmic delivery systems, and integration with digital health monitoring for chronic conditions</strong>.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/275150/asia-southeast-betaxolol-forecast-market">
            https://www.24chemicalresearch.com/reports/275150/asia-southeast-betaxolol-forecast-market</a></b></div><br>
            <b>Table of Content:</b><p><h2><span style="font-size:16px"><strong>1 Market Overview&nbsp;&nbsp; &nbsp;</strong></span></h2><br />
<br />
<p>1.1 Product Overview and Scope of Betaxolol&nbsp;</p><br />
<br />
<h2><strong><span style="font-size:16px">1.2 Segment by Type&nbsp;&nbsp; &nbsp;</span></strong></h2><br />
<br />
<p>1.2.1 Southeast Asia Market Size YoY Growth Rate Analysis by Type: 2023 VS 2030&nbsp;&nbsp; &nbsp;<br /><br />
1.2.2 Liquid&nbsp;&nbsp; &nbsp;<br /><br />
1.2.3 Tablet<br /><br />
1.2.4 Others<br /><br />
<br />
<h2><span style="font-size:16px"><strong>1.3 Segment by Application&nbsp;&nbsp;</strong></span></h2><br />
<br />
<p>1.3.1 Southeast Asia Market Size YoY Growth Rate Analysis by Application: 2023 VS 2030&nbsp;&nbsp; &nbsp;<br /><br />
1.3.2&nbsp;&nbsp; &nbsp;Pharmaceutical intermediates<br /><br />
1.3.3&nbsp;&nbsp; &nbsp;Chemical intermediate<br /><br />
1.3.4&nbsp;&nbsp; &nbsp;Others<br /><br />
1.4 Southeast Asia Market Growth Prospects&nbsp;&nbsp; &nbsp;<br /><br />
1.4.1 Southeast Asia Revenue Estimates and Forecasts (2019-2030)&nbsp;&nbsp; &nbsp;<br /><br />
1.4.2 Southeast Asia Production Estimates and Forecasts (2019-2030)&nbsp;&nbsp;</p><br />
<br />
<h2><span style="font-size:16px"><strong>2 Southeast Asia Growth Trends&nbsp;&nbsp; &nbsp;</strong></span></h2><br />
<br />
<p>2.1 Industry Trends&nbsp;&nbsp; &nbsp;<br /><br />
2.1.1 SWOT Analysis&nbsp;&nbsp; &nbsp;<br /><br />
2.1.2 PESTEL Analysis&nbsp;&nbsp; &nbsp;<br /><br />
2.1.3 Porter&rsquo;s Five Forces Analysis&nbsp;&nbsp; &nbsp;<br /><br />
2.2 Potential Market and Growth Potential Analysis&nbsp;&nbsp; &nbsp;</p><br />
<br />
<h2><span style="font-size:16px"><strong>3 Market Co</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/275150/asia-southeast-betaxolol-forecast-market">
            https://www.24chemicalresearch.com/reports/275150/asia-southeast-betaxolol-forecast-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>